

Why a Pediatric & SDH-Deficient GIST Consortium?

Pediatric and SDH-deficient GIST patients live with a rare form of Gastrointestinal Stromal Tumors (GIST). Although rare, they represent a mighty force with a strong, global support network. These patients face a disease that has limited treatment options. Historically, clinicians and researchers worked independently and saw very few patients, who were at one time labeled 'Wildtype'. Few effective therapies exist despite the research efforts of the National Institutes of Health's (NIH) Wildtype GIST Clinic or the UK-based PAWS GIST Clinic.

Because of the need to advance research and for clinicians and research teams to collaborate, The Life Raft Group spearheaded the launch and creation of the Pediatric & SDH-Deficient GIST Consortium at the Biden Cancer Summit in 2018. The aim of the Consortium is to extend and sustain the work of the NIH and UK Clinics and other research efforts with the ultimate goal of finding a cure through global collaboration.

As patients' survival and quality of life are dramatically impacted by this disease, it is urgent that the leading Pediatric & SDH-deficient GIST experts collaborate and share data and tissue, with the goal of finding successful targeted therapies that can help keep these patients alive.

For more information on our collaborative efforts in SDH research, visit this link:

https://liferaftgroup.org/pediatric-sdh-deficient-gist-consortium/

Members of The Pediatric & SDH-Deficient GIST Consortium Include Clinical/Research Partners:

- Sosipatros Boikos, MD Georgetown Lombardi Comprehensive Cancer Center
- Venkata Ramesh Bulusu, MD
 Cambridge University Hospitals, UK
- Ruth Casey, PhD
 Cambridge University Hospitals, UK
- Suzanne George, MD
 Dana-Farber Cancer Institute
- Olivier Giger, MD
 Cambridge University Hospitals, UK
- Eyal Gottlieb, MSc, PhD MD Anderson Cancer Center
- Michael Heinrich, MD
 Oregon Health and Science University
- Lee Helman, MD
 Osteosarcoma Institute
- Katherine Janeway, MD Dana-Farber Cancer Institute
- Jonathan Keith Killian, MD, PhD Foundation Medicine

- Michael P. LaQuaglia, MD
 Memorial Sloan Kettering Cancer Center
- Margaret von Mehren MD Fox Chase Cancer Center
- Markku Martti Miettinen, MD National Cancer Institute
- Maria Pantaleo, MD University of Bologna, Italy
- Alberto S. Pappo, MD
 St. Jude Children's Research Hospital
- Karel Pacak, D.Sc., MD, PhD National Institutes of Health
- Joshua Schiffman, MD Huntsman Cancer Institute
- Jason Sicklick, MD
 Moores Cancer Center, UCSD
- Jonathan Trent, MD
 Sylvester Comprehensive Cancer Center
- Christopher B. Weldon, MD, PhD Boston Children's Hospital

- Sebastian Bauer, MD West German Cancer Center, Germany
- Anthony Gill, MD
 University of Sydney, Australia
- John Glod, MD
 National Institutes of Health
- Eamonn Maher, MD Cambridge University Hospitals, UK
- Paul Meltzer, MD National Cancer Institute
- Neeta Somaiah, MD MD Anderson Cancer Center
- Farzana Pashankar, MD, MRCP, MBBS Yale School of Medicine
- Neeltje Steeghs, MD
 Netherlands Cancer Institute

Patient Advocacy Partners Include:

- Phyllis Gay, GIST Support International
- Jayne Bressington, GIST Support UK

- Becky Owens, The Life Raft Group
- Sara Rothschild, MPH, The Life Raft Group

Founding Members





